Síndrome de Guillain Barré asociado a Brucelosis

Montalvo, Raúl; García, Yury E.; Ñavincopa, Marcos; Ticona, Eduardo; Chávez, Gonzalo; Moore, David

doi:10.1590/s1726-46342010000200020

Cited by 6 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brucella canis is less pathogenic to people when compared to other Brucellae , but rare reports of severe clinical presentations including endocarditis, polyarthritis, meningitis, aneurysms and peritonitis exist (Tosi and Nelson 1982, McKee and Ballard 1999, Piampiano and others 2000, Manias and others 2013). There is also a report of B canis neurobrucellosis resembling Guillain‐Barré syndrome (Zadeh and Fard 2007), an increasingly reported association among other Brucellae species (Namiduru and others 2003, Watanabe and others 2005, Montalvo and others 2010, Babamahmoodi and Babamahmoodi 2011).…”

Section: What Are the Clinical Signs In People?mentioning

confidence: 95%

Brucella canis: a clinical review and rationalising risk

Woods

2024

In Practice

View full text Add to dashboard Cite

Background: After a letter published by the chief veterinary officer in February 2021 highlighted an increase in the number of positive Brucella canis dogs, the frequency of B canis testing in the UK has increased substantially. To date, roughly 160 positive cases have been reported by the APHA. Amid growing unease, veterinary teams have implemented practice protocols to mitigate risk associated with this non‐endemic, zoonotic infection. Although well‐meaning, blanket policy and inappropriate application of serological tests can negatively impact client and patient welfare while fuelling health anxiety among staff. The combination of increased pet travel, increased popularity of importing dogs and a lack of centralised border requirements for dogs, means B canis is likely to be increasingly encountered and warrants regular, evidence‐based discussion to empower the profession and preserve canine welfare.Aim of the article: This article summarises the clinically relevant issues surrounding Brucella canis, focussing on epidemiology, transmission, human health and safety, clinical signs, diagnosis and treatment. Governmental recommendations and recent risk assessments by the Human Animal Infection and Risk Surveillance group are drawn on where appropriate. Moreover, the article aims to instil confidence in veterinary personnel when rationalising B canis infection risk, and help to ensure that canine and staff health are protected.

show abstract

Section: What Are the Clinical Signs In People?mentioning

confidence: 95%

Brucella canis: a clinical review and rationalising risk

Woods

2024

In Practice

View full text Add to dashboard Cite

show abstract

“…In 1987, five GBS cases were associated with a viral infection caused by a rabies vaccine prepared with the brain of a lactating mouse (Cabrera, Griffin, & Johnson, 1987). In 2010, a GBS case was reported associated to Brucellosis, an infectious disease caused by Brucella bacteria genus (Montalvo et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Guillain–Barre syndrome outbreak in Peru: Association with polymorphisms in IL‐17, ICAM1, and CD1

Jaramillo‐Valverde

Levano²,

Villanueva

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

BackgroundGuillain–Barre Syndrome (GBS) is considered a complex disorder with significant environmental effect and genetic susceptibility. Genetic polymorphisms in CD1E, CD1A, IL‐17, and/or ICAM1 had been proposed as susceptibility genetic variants for GBS mainly in Caucasian population. This study explores the association between selected polymorphisms in these genes and GBS susceptibility in confirmed GBS cases reported in mestizo population from northern Peru during the most recent GBS outbreak of May 2018.MethodsA total of nine nonrelated cases and 11 controls were sequenced for the polymorphic regions of CD1A, CD1E, IL‐17, and ICAM1.ResultsWe found a significant protective association between heterozygous GA genotype in ICAM1 (241Gly/Arg) and GBS (p < .047). IL‐17 was monomorphic in both controls and patients. No significant differences were found in the frequency of SNPs in CD1A and CD1E between the group with GBS patients and healthy controls.ConclusionICAM1 polymorphisms might be considered as potential genetic markers of GBS susceptibility. Further studies with larger sample size will be required to validate these findings.

show abstract

Guillain–Barré syndrome in Colombia: where do we stand now?

Mahecha

Ojeda²,

Vega³

et al. 2016

Immunol Res

View full text Add to dashboard Cite

Guillain-Barré syndrome (GBS) is a rapid-onset muscle weakness disease caused by the immune-mediated damage of the peripheral nervous system. Since there is an increase incidence of GBS cases in Latin America, particularly in Colombia, and most of them are currently preceded by Zika virus (ZIKV) infection, we aimed to assess the available evidence of the disease in Colombia through a systematic literature review. Out of 51 screened abstracts, only 16 corresponded to articles that met inclusion criteria, of which 15 were case reports or case series. A total of 796 cases of GBS were reported in the included articles. The majority of patients were males (66.8 %) and younger than 50 years old (94 %). An infectious disease before the onset of GBS was registered in 31 % of patients, with gastrointestinal or respiratory symptoms being the most frequently observed. In those cases in which electrodiagnostic tests were performed, the most common subphenotype was acute inflammatory demyelinating polyneuropathy (17 %). Death was reported in 15 % of patients. Data regarding GBS in Colombia is scant and heterogeneous. Taking into account the burden of the disease and the recent rise of GBS cases associated with ZIKV, a careful patient evaluation and a systematic collection of data are warranted. A form to data gathering is proposed.

show abstract

Síndrome de Guillain Barré asociado a Brucelosis

Cited by 6 publications

References 12 publications

Brucella canis: a clinical review and rationalising risk

Brucella canis: a clinical review and rationalising risk

Guillain–Barre syndrome outbreak in Peru: Association with polymorphisms in IL‐17, ICAM1, and CD1

Guillain–Barré syndrome in Colombia: where do we stand now?

Contact Info

Product

Resources

About